A rational approach to maximize success rate in target discovery

Area of Science:

• Biochemistry
• Genomics
• Pharmacology

Background:

• High attrition rates in drug discovery necessitate improved strategies for target identification and validation.
• Early-stage selection of suitable drug targets is crucial for efficient lead discovery and optimization.

Purpose of the Study:

• To implement and demonstrate an efficient strategy for identifying, selecting, characterizing, and validating drug targets.
• To reduce attrition rates in drug discovery by ensuring targets are well-suited for small-molecule inhibitor development.

Main Methods:

• Target Selection: Gene expression analysis in clinical and in vitro samples to identify disease-relevant targets with specific tissue distribution.
• Target Assessment: Three-dimensional protein structure analysis to evaluate binding site characteristics, drugability, and selectivity for small-molecule inhibitors.
• Target Validation: In vitro functional studies to confirm the role of the target in disease models and support the therapeutic hypothesis.

Main Results:

• Successful identification of drug targets through a multi-faceted rational approach.
• Characterization of targets for drugability and selectivity, minimizing potential in vivo side effects.
• Validation of targets provides a strong biological basis for therapeutic concepts.

Conclusions:

• The implemented strategy significantly enhances the drug discovery process by improving early-stage target selection.
• This rational approach increases the probability of discovering selective small-molecule inhibitors with therapeutic efficacy.
• The method aims to maximize the likelihood of success in lead discovery and development, reducing overall attrition.